Skip to main content
SpringerLink
Log in
Book cover

Gastrointestinal Oncology pp 205–224Cite as

Unresectable Pancreatic Cancer

  • Chapter
  • First Online:

  • 1655 Accesses

Abstract

Adenocarcinoma of the pancreas is a common and lethal disease. Most cases of pancreatic cancer are not resectable, presenting either as locally advanced or metastatic disease. The prognosis for locally advanced and metastatic pancreatic cancer is poor, but the use of chemotherapy and radiation therapy does improve survival and symptoms. For locally advanced pancreatic cancer, standard approaches include either 5-FU based chemoradiotherapy or gemcitabine based chemotherapy or both. Ongoing studies are assessing the role of induction chemotherapy followed by chemoradiotherapy, and the use of biological therapy with radiotherapy in locally advanced disease. For metastatic pancreatic cancer the standard treatments include systemic therapy with gemcitabine or gemcitabine combined with the EGFR tyrosine kinase inhibitor erlotinib. Ongoing studies are assessing the efficacy of other biological agents, and novel systemic combinations for metastatic disease. Further advances in unresectable pancreatic cancer will require an improved understanding of tumor biology and molecular predictive models.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Alberts SR, Townley PM, Goldberg RM et al (2003) Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a north central cancer treatment group phase II study. Ann Oncol 14:580–585

    Article  CAS  PubMed  Google Scholar 

  • Baumann M, Krause M, Dikomey E et al (2007) EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83:238–248

    Article  CAS  PubMed  Google Scholar 

  • Blackstock AW, Tepper JE, Niedwiecki D et al (2003) Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 34:107–116

    Article  CAS  PubMed  Google Scholar 

  • Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578

    Article  CAS  PubMed  Google Scholar 

  • Bramhall SR, Schulz J, Nemunaitis J et al (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167

    Article  CAS  PubMed  Google Scholar 

  • Brodowicz T, Wolfram RM, Kostler WJ et al (2000) Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs 11:623–628

    Article  CAS  PubMed  Google Scholar 

  • Burris HA III, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    CAS  PubMed  Google Scholar 

  • Cascinu S, Labianca R, Catalano V et al (2003) Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian group for the study of digestive tract cancer (GISCAD). Ann Oncol 14:205–208

    Article  CAS  PubMed  Google Scholar 

  • Cascinu S, Berardi R, Labianca R et al (2008) Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 9:39–44

    Article  CAS  PubMed  Google Scholar 

  • Chang BW, Saif MW (2009) Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap? JOP 10:231–236

    PubMed  Google Scholar 

  • Chang DT, Schellenberg D, Shen J et al (2009) Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 115:665–672

    Article  PubMed  Google Scholar 

  • Chauffert B, Mornex F, Bonnetain F et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19:1592–1599

    Article  CAS  PubMed  Google Scholar 

  • Ciardiello F, Caputo R, Troiani T et al (2001) Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 93:172–178

    Article  CAS  PubMed  Google Scholar 

  • Cohen SJ, Dobelbower R Jr, Lipsitz S et al (2005) A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62:1345–1350

    Article  CAS  PubMed  Google Scholar 

  • Colucci G, Giuliani F, Gebbia V et al (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the gruppo oncologia dell’italia meridionale. Cancer 94:902–910

    Article  CAS  PubMed  Google Scholar 

  • Colucci G, Labianca R, Costanza V et al (2009) A randomized trial of gemcitabine versus gemcitabine plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: the GIP-1 (gruppo italiano pancreas- GOIM/GISCAD/GOIRC) study. J Clin Oncol 27 (Abstr 4504)

    Google Scholar 

  • Crown J, Casper ES, Botet J et al (1991) Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 9:1682–1686

    CAS  PubMed  Google Scholar 

  • Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  CAS  PubMed  Google Scholar 

  • Cunningham D, Chau I, Stocken D et al (2005) Phase III randomised comparison of gemicitabine (GEM) with gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl 3:12

    Google Scholar 

  • Cunningham D, Chau I, Stocken DD et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513–5518

    Article  CAS  PubMed  Google Scholar 

  • Czito BG, Willett CG, Bendell JC et al (2006) Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 24:656–662

    Article  CAS  PubMed  Google Scholar 

  • Dhillon N, Aggarwal BB, Newman RA et al (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491–4499

    Article  CAS  PubMed  Google Scholar 

  • Duffy A, Kortmansky J, Schwartz GK et al (2008) A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19:86–91

    Article  CAS  PubMed  Google Scholar 

  • Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80:751–755

    Article  Google Scholar 

  • Glimelius B, Hoffman K, Sjoden PO et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600

    CAS  PubMed  Google Scholar 

  • Hazel JJ, Thirlwell MP, Huggins M et al (1981) Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol 32:164–165

    CAS  PubMed  Google Scholar 

  • Heinemann V, Wilke H, Mergenthaler HG et al (2000) Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11:1399–1403

    Article  CAS  PubMed  Google Scholar 

  • Heinemann V, Quietzsch D, Gieseler F et al (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946–3952

    Article  CAS  PubMed  Google Scholar 

  • Heinemann V, Labianca R, Hinke A et al (2007) Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a german multicenter study. Ann Oncol 18:1652–1659

    Article  CAS  PubMed  Google Scholar 

  • Herrmann R, Bodoky G, Ruhstaller T et al (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212–2217

    Article  CAS  PubMed  Google Scholar 

  • Hess V, Salzberg M, Borner M et al (2003) Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 21:66–68

    Article  CAS  PubMed  Google Scholar 

  • Hochster HS (2003) Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents. Int J Radiat Oncol Biol Phys 56:24–30

    Article  CAS  PubMed  Google Scholar 

  • Hofheinz R, Wenz F, Post S et al (2009) Capecitabine (cape) versus 5-fluorouracil (5-FU)-based neo-adjuvant chemotherapy for locally advanced rectal cancer (LARC): safety results of a randomized, phase III trial. J Clin Oncol 27:4014

    Article  Google Scholar 

  • Hoyer M, Roed H, Sengelov L et al (2005) Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 76:48–53

    Article  PubMed  Google Scholar 

  • Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166–2174

    CAS  PubMed  Google Scholar 

  • Hughes AN, O’Brien ME, Petty WJ et al (2009) Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 27:1220–1226

    Article  CAS  PubMed  Google Scholar 

  • Huguet F, Andre T, Hammel P et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326–331

    Article  CAS  PubMed  Google Scholar 

  • Huguet F, Girard N, Guerche CS et al (2009) Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 27:2269–2277

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  CAS  PubMed  Google Scholar 

  • Iannitti D, Dipetrillo T, Akerman P et al (2005) Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28:570–575

    Article  CAS  PubMed  Google Scholar 

  • Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  • Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806

    Article  CAS  PubMed  Google Scholar 

  • Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048

    Article  CAS  PubMed  Google Scholar 

  • Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

    Article  CAS  PubMed  Google Scholar 

  • Katz MH, Pisters PW, Evans DB et al (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206:833–846; discussion 846–848

    Google Scholar 

  • Kindler HL, Friberg G, Singh DA et al (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033–8040

    Article  CAS  PubMed  Google Scholar 

  • Kindler H, Niedzwiecki D, Hollis D et al (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine puls placebo (P) in patients (pts) with a dvanced pancreatic cancer (PC): a preliminary analysis of cancer and leukemia group B (CALGB). J Clin Oncol 25 (Abstr 4508)

    Google Scholar 

  • Kindler HL, Gangadhar T, Karrison T et al (2008) Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC). J Clin Oncol 26 (Abstr 4502)

    Google Scholar 

  • Klaassen DJ, MacIntyre JM, Catton GE et al (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil – an Eastern Cooperative Oncology Group study. J Clin Oncol 3:373–378

    CAS  PubMed  Google Scholar 

  • Ko AH, Quivey JM, Venook AP et al (2007) A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 68:809–816

    Article  CAS  PubMed  Google Scholar 

  • Krishnan S, Rana V, Janjan NA et al (2007) Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 110:47–55

    Article  PubMed  Google Scholar 

  • Krzyzanowska MK, Weeks JC, Earle CC (2003) Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol 21:3409–3414

    Article  PubMed  Google Scholar 

  • Kulke MH, Blaszkowsky LS, Ryan DP et al (2007) Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787–4792

    Article  CAS  PubMed  Google Scholar 

  • Li CP, Chao Y, Chi KH et al (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57:98–104

    Article  CAS  PubMed  Google Scholar 

  • Loehrer PJ, Powell ME, Cardenes HR et al (2008) A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer. J Clin Oncol 26:4506

    Google Scholar 

  • Louvet C, Andre T, Lledo G et al (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20:1512–1518

    Article  CAS  PubMed  Google Scholar 

  • Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509–3516

    Article  CAS  PubMed  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  CAS  PubMed  Google Scholar 

  • Mallinson CN, Rake MO, Cocking JB et al (1980) Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 281:1589–1591

    Article  CAS  PubMed  Google Scholar 

  • Mamon HJ, Niedzwiecki D, Hollis DR et al (2005) Preliminary analysis of cancer and leukemia group B (CALGB) 80003: a phase II trial of gemcitabine, 5-fluorouracil (5FU), and radiation therapy (RT) in locally advanced non-metastatic pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 63:s13

    Google Scholar 

  • Maurel J, Martin-Richard M, Conill C et al (2006) Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 66:1391–1398

    Article  CAS  PubMed  Google Scholar 

  • Moertel CG, Frytak S, Hahn RG et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the gastrointestinal tumor study group. Cancer 48:1705–1710

    Article  CAS  PubMed  Google Scholar 

  • Moore MJ, Hamm J, Dancey J et al (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 21:3296–3302

    Article  CAS  PubMed  Google Scholar 

  • Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966

    Article  CAS  PubMed  Google Scholar 

  • Munter M, Timke C, Abdollahi A et al (2008) Final results of a phase II trial [PARC-study ISRCTN56652283] for patients with primary inoperable locally advanced pancreatic cancer combining intensity-modulated radiotherapy (IMRT) with cetuximab and gemcitabine. J Clin Oncol 26 (Abstr 4613)

    Google Scholar 

  • Oettle H, Richards D, Ramanathan RK et al (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639–1645

    Article  CAS  PubMed  Google Scholar 

  • O’Reilly R, Abou-Alfa G, Letourneau R et al (2004) A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemicitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC). J Clin Oncol 23 (Abstr LBA4006)

    Google Scholar 

  • Palmer KR, Kerr M, Knowles G et al (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81:882–885

    Article  CAS  PubMed  Google Scholar 

  • Peeters M, Siena S, Van Cutsem E et al (2009) Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 97(11):1469–1474

    Google Scholar 

  • Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26 (Abstr 4508)

    Google Scholar 

  • Philip PA, Zalupski MM, Vaitkevicius VK et al (2001) Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92:569–577

    Article  CAS  PubMed  Google Scholar 

  • Philp P, Benedetti J, Fenoglio-Preiser C et al (2007) Phase III study of gemcitabine [G] plus cetuximan [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 25 (Abstr LBA4509)

    Google Scholar 

  • Poplin E, Levy D, Berlin J et al (2006) Phase III trial of gemitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR] versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 25 (Abstr LBA4004)

    Google Scholar 

  • Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778–3785

    Article  CAS  PubMed  Google Scholar 

  • Rich T, Harris J, Abrams R et al (2004) Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 27:51–56

    Article  CAS  PubMed  Google Scholar 

  • Rocha Lima CM, Green MR, Rotche R et al (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776–3783

    Article  CAS  PubMed  Google Scholar 

  • Ruano-Ravina A, Almazan Ortega R, Guedea F (2008) Intraoperative radiotherapy in pancreatic cancer: a systematic review. Radiother Oncol 87:318–325

    Article  PubMed  Google Scholar 

  • Saif MW, Eloubeidi MA, Russo S et al (2005) Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 23:8679–8687

    Article  CAS  PubMed  Google Scholar 

  • Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

    Article  CAS  PubMed  Google Scholar 

  • Scheithauer W, Schull B, Ulrich-Pur H et al (2003) Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 14:97–104

    Article  CAS  PubMed  Google Scholar 

  • Schneider BJ, Ben-Josef E, McGinn CJ et al (2005) Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63:1325–1330

    Article  CAS  PubMed  Google Scholar 

  • Shepard RC, Levy DE, Berlin JD et al (2004) Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the Eastern Cooperative Oncology Group. Oncology 66:303–309

    Article  CAS  PubMed  Google Scholar 

  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    Article  CAS  PubMed  Google Scholar 

  • Shinchi H, Takao S, Noma H et al (2002) Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53:146–150

    Article  CAS  PubMed  Google Scholar 

  • Spano JP, Chodkiewicz C, Maurel J et al (2008) Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371:2101–2108

    Article  CAS  PubMed  Google Scholar 

  • Stathopoulos GP, Syrigos K, Aravantinos G et al (2006) A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95:587–592

    Article  CAS  PubMed  Google Scholar 

  • Sultana A, Tudur Smith C, Cunningham D et al (2007) Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96:1183–1190

    Article  CAS  PubMed  Google Scholar 

  • Talamonti MS, Catalano PJ, Vaughn DJ et al (2000) Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 18:3384–3389

    CAS  PubMed  Google Scholar 

  • Tang P, Gill S, Au HJ et al (2009) Phase II trial of erlotinib in advanced pancreatic cancer. J Clin Oncol 27:4609

    Article  Google Scholar 

  • Tempero M, Plunkett W, Ruiz Van Haperen V et al (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408

    Article  CAS  PubMed  Google Scholar 

  • Touroutoglou N, Gravel D, Raber MN et al (1998) Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9:1003–1008

    Article  CAS  PubMed  Google Scholar 

  • Van Cutsem E, van de Velde H, Karasek P et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438

    Article  PubMed  Google Scholar 

  • Van Cutsem E, Peeters M, Siena S et al (2007a) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664

    Article  PubMed  Google Scholar 

  • Van Cutsem E, Humblet Y, Gelderblom H et al (2007) Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. Proceedings of the Gastrointestinal Cancers Symposium (Abstr 237)

    Google Scholar 

  • Van Cutsem E, Verslype C, Grusenmeyer PA (2007c) Lessons learned in the management of advanced pancreatic cancer. J Clin Oncol 25:1949–1952

    Article  PubMed  Google Scholar 

  • Van Cutsem E, Vervenne WL, Bennouna J et al (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231–2237

    Article  PubMed  Google Scholar 

  • Wilkowski R, Boeck S, Ostermaier S et al (2009) Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study. Br J Cancer 101:1853–1859

    Article  CAS  PubMed  Google Scholar 

  • Wolpin BM, Hezel AF, Abrams T et al (2009) Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27:193–198

    Article  CAS  PubMed  Google Scholar 

  • Xiong HQ, Rosenberg A, LoBuglio A et al (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22:2610–2616

    Article  CAS  PubMed  Google Scholar 

  • Yip D, Karapetis C, Strickland A et al (2006) Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 3:CD002093

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Princess Margaret Hospital, 5-708, 610 University Avenue, Toronto, ON, M5G 2M9, Canada

    Daniel Renouf & Malcolm Moore

  2. Department of Radiation Oncology, Princess Margaret Hospital, 5-708, 610 University Avenue, Toronto, ON, M5G 2M9, Canada

    Laura A. Dawson

Authors
  1. Daniel Renouf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura A. Dawson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Malcolm Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Malcolm Moore .

Editor information

Editors and Affiliations

  1. Div. Medical Oncology, University of British Columbia, West 10th Avenue 600, Vancouver, V5Z 4E6, British Columbia, Canada

    Charles D. Blanke

  2. FB 19 Zentrum der Radiologie, Klinik f. Strahlentherapie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, Frankfurt, 60590, Germany

    Claus Rödel

  3. Evanston Northwestern Healthcare, Northwestern University, Ridge Ave. 2650, Evanston, 60201, Illinois, USA

    Mark S. Talamonti

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Renouf, D., Dawson, L.A., Moore, M. (2011). Unresectable Pancreatic Cancer. In: Blanke, C., Rödel, C., Talamonti, M. (eds) Gastrointestinal Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13306-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-13306-0_8

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-13305-3

  • Online ISBN: 978-3-642-13306-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation